Nuropod, a Parasym product, has announced U.S. availability of its wearable vagus nerve stimulation device designed for daily at-home sessions, with HSA and FSA payments accepted through Truemed.

Sacramento, United States, October 6, 2026 /PressCable/ -- Nuropod has announced U.S. availability of its wearable vagus nerve stimulation device, giving adults a way to incorporate daily sessions into their home routines without a clinic visit.

More information is available at https://nuropod.com/products/nuropod.

The announcement comes as everyday stress remains a common concern for U.S. adults, with a growing number seeking ways to support rest and recovery within their existing routines. According to the American Psychological Association's 2024 Stress in America report, work and finances remain among the most cited stressors for American adults. Nuropod's wearable is designed to give adults a straightforward way to build nervous system care into their daily routine.

The device itself is a small wearable that fits like a headphone, with an earpiece that sits on the tragus, the part of the outer ear just in front of the ear canal, where the vagus nerve reaches the skin. The vagus nerve carries signals between the brain and organs including the heart, lungs, and gut, and plays a large part in how the body handles stress, rest, and recovery.

"Non-invasive vagus nerve stimulation uses gentle electrical impulses delivered through the ear to stimulate a branch of the vagus nerve. This is designed to provide the nervous system with a more direct signal that supports the body's rest and recovery response," said Dr. Elisabetta Burchi, Head of Research at Parasym.

Users apply a small amount of moisture to the left tragus, fit the earpiece with its malleable cable behind the ear, and raise the intensity until they feel a light tingling. Most people use the device for around 30 minutes, once or twice a day, while working, reading, or watching television.

Each kit includes the device, earpiece, charger, protective case, and quick start guide. HSA and FSA funds are accepted through Truemed.

The patented, third-party certified device is the result of more than 10 years of research and development, with over $10 million invested in clinical studies and more than 150 research partners. Its underlying technology, Parasym's proprietary AVNT waveform, has been studied across a broad range of populations in randomized, placebo-controlled studies, with more than 60 completed and over 100 ongoing. In clinical studies, participants reported an average 35% reduction in anxious thoughts.

Individuals interested in learning more may visit https://nuropod.com/

Disclaimer: Research referenced in this article was conducted using Parasym’s neuromodulation technology under research conditions. Findings relate to specific study populations and should not be interpreted as guaranteed individual outcomes. Nuropod is classified by the FDA as a non-significant risk device and is not intended to diagnose, treat, cure, or prevent any disease.

Contact Info:
Name: PR Team
Email: Send Email
Organization: Nuropod by Parasym
Address: 2108 N Street, Sacramento, California 95816, United States
Website: https://nuropod.com/

Source: PressCable

Release ID: 89205383

Should you come across any errors, concerns, or inconsistencies within this press release's content, we urge you to reach out without delay by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our committed team will promptly address your feedback within 8 hours and take appropriate measures to resolve any identified issues or guide you through the removal process. Providing accurate and dependable information remains our utmost priority.